Evaluating new tests for bloodstream infections
Duration of Bloodstream Infection as Measured by Conventional Cultures Compared With Novel Culture Independent Systems and Persistence of Biomarkers Associated With Severe Infection
This study is testing new blood tests to see if they can help doctors understand how long bacterial infections last and when it's safe to change treatments for patients with bloodstream infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Queensland Academic / other |
| Locations | 3 sites (Brisbane, Queensland and 2 other locations) |
| Trial ID | NCT04821661 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the duration of bloodstream infections caused by bacteria and how it correlates with clinical outcomes. It utilizes two novel diagnostic technologies: the T2 magnetic resonance assay, which detects bacteria more sensitively than traditional methods, and the SeptiCyte RAPID test, which assesses the body's inflammatory response. By comparing these new methods with standard blood culture techniques, the study aims to provide insights into the persistence of infections and inform treatment decisions. The findings could help determine when to switch from intravenous antibiotics to oral medications and potentially allow for earlier hospital discharges.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed bloodstream infections caused by specific pathogens detectable by the T2 assay.
Not a fit: Patients receiving palliative care or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of bloodstream infections, allowing for timely treatment adjustments and better patient outcomes.
How similar studies have performed: Other studies have shown promise with similar diagnostic approaches, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have proven bloodstream infection with any T2-on panel pathogen (Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Candida spp.) Exclusion Criteria: * Palliative care approach * Failure to give written informed consent (by patient or their legal representative) * Polymicrobial index blood culture
Where this trial is running
Brisbane, Queensland and 2 other locations
- Caboolture Hospital — Brisbane, Queensland, Australia (Not_yet_recruiting)
- Redcliffe Hospital — Brisbane, Queensland, Australia (Not_yet_recruiting)
- Royal Brisbane and Women's Hospital — Brisbane, Queensland, Australia (Recruiting)
Study contacts
- Study coordinator: Tiffany Harris-Brown
- Email: t.harrisbrown@uq.edu.au
- Phone: +61 7 3346 6072
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.